Polypill with or without aspirin in persons without cardiovascular disease

Polypill with or without aspirin in persons without cardiovascular disease

BACKGROUND A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease. METHODS Using a 2-by-2-by-2 factorial design, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART...

Full description

Bibliographic Details
Main Authors: Bosch, J. (Author), Christou, C. (Author), Dagenais, G. (Author), Dans, A. (Author), Gamra, H. (Author), Gao, P. (Author), Girish, P. (Author), Joseph, P. (Author), Lopez-Jaramillo, P. (Author), McCready, T. (Author), Pais, P. (Author), Rocha, C. (Author), Santoso, A. (Author), Talukder, S. (Author), Teo, K. (Author), Tyrwhitt, J. (Author), Xavier, D. (Author), Xavier, F. (Author), Yeates, K. (Author), Yusoff, K. (Author), Yusuf, S. (Author)
Format: Article
Language:English
Published: Massachussetts Medical Society 2021
Series:New England Journal of Medicine
Subjects:
acetylsalicylic acid
adult
aged
Aged
Anticholesteremic Agents
antihypertensive agent
Antihypertensive Agents
antithrombocytic agent
Article
Aspirin
atenolol
Atenolol
blood
blood pressure
Blood Pressure
cardiovascular disease
Cardiovascular Diseases
cardiovascular mortality
cerebrovascular accident
Cholesterol, LDL
clinical outcome
clinical trial
combination drug therapy
controlled study
dizziness
double blind procedure
drug combination
Drug Combinations
drug effect
drug safety
Drug Therapy, Combination
drug withdrawal
dyspepsia
female
Female
follow up
gastritis
gastrointestinal hemorrhage
heart arrest
heart failure
heart infarction
heart muscle revascularization
human
Humans
hydrochlorothiazide
Hydrochlorothiazide
hypocholesterolemic agent
hypotension
incidence
Incidence
low density lipoprotein cholesterol
low density lipoprotein cholesterol level
low drug dose
male
Male
Medication Adherence
medication compliance
middle aged
Middle Aged
mortality
multicenter study
muscle disease
peptic ulcer
placebo
Platelet Aggregation Inhibitors
priority journal
ramipril
randomized controlled trial
risk factor
Risk Factors
simvastatin
Simvastatin
systolic blood pressure
vitamin D
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items